In order to assess the effects of systemic exposure to JAK2 inhibitors on atherosclerosis, we fed ApoE-null mice with HCD with or without ruxolitinib for 16 weeks, starting at 6 weeks of age, and assessed for atherosclerotic burden. Here, JAK2 is linked to atherosclerosis.